Reviewer's report

Title: Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature

Version: 1 Date: 30 December 2012

Reviewer: Sam Schulman

Reviewer's report:

Major Compulsory Revisions
1. The authors talk about "aged" patients but the case is 59 y.o., which most of us would not consider elderly, and definitely not geriatric. Thus the discussion and conclusion should not be restricted to "aged patients"

2. The report of the case is unnecessary long and should be concentrated. Also Table 1 contains duplicate information and details that are not required for this report and should be deleted. Just add in the case presentation that INR 5 days after the first dose reduction was 2.29.

3. Figure 1: I can’t see the bar that is supposed to indicate the duration of rifampicin therapy. Please clarify.

4. The increased need for warfarin after initiation of rifampicin is well known and the description of details in all studies that have demonstrated that in the past is superfluous. I suggest shortening the Figure 2 – which in my opinion is a Table – to contain only the last 3 studies. These also reported the increased sensitivity after stopping rifampicin. A comment in the text or another column should be added whether the supratherapeutic INRs in those studies were associated with bleeding.

5. The Discussion also needs shortening to focus on the case. The third paragraph should be deleted. Also other paragraphs should be shortened and the text ought to be better organized. The emphasis should be on the need for weekly monitoring after stopping rifampicin, until the maintenance dose of warfarin has decreased to what it was before rifampicin.

Minor Essential Revisions
1. ABSTRACT, background: Suggest shortening “The co-administration of rifampicin and warfarin in older patients with atrial fibrillation may lead to adverse drug events. We aimed at reporting, for the first time” to “The co-administration of rifampicin and warfarin may lead to adverse drug events. We report for the first time”

2. ABSTRACT, Case presentation: (therapeutic range, INR 2.0-3.0) (and also later in the manuscript, because the target INR is 2.5 but 2.0-3.0 is a range)

3. BACKGROUND, end of 2nd para: The sentence “bleeding events and INR values during co-administration of rifampicin and warfarin” should be modified since the event occurred after the treatment with rifampicin had been concluded.
Write instead “bleeding events and INR values after termination of co-administration …”

**Level of interest:** An article of importance in its field

**Quality of written English:** Needs some language corrections before being published

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

'I declare that I have no competing interests’